Exploring the Role of Calcium Sensing Receptor in Septic Shock
Official title: Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock
Run by Centre Hospitalier Universitaire, Amiens · NCT06853340 · Data updated 2026-11-12
This study is trying to see how a specific receptor in the immune cells of patients with septic shock affects their body's response and calcium levels, which could lead to new treatment options.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Amiens) |
| Status | Recruiting |
| Started | February 24, 2025 |
| Main results expected | April 1, 2025 |
| Study ends | February 2027 |
| Registry record updated | April 25, 2025 |
| Trial ID | NCT06853340 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old who are in septic shock and have elevated lactate levels.
✕Probably not a fit
Patients with hemorrhagic shock, certain genetic disorders, or those on immunosuppressive treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the expression of the Calcium Sensing Receptor (CaSR) in monocytes of patients experiencing septic shock. It aims to understand how CaSR activation affects immune responses and calcium balance during this critical condition. By analyzing blood samples from intensive care patients within the first 24 hours of septic shock, the study seeks to identify potential therapeutic implications related to CaSR modulation. This research could provide insights into the phosphocalcic disturbances commonly observed in septic shock.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies targeting CaSR to improve outcomes in septic shock patients.
How similar studies have gone: While this approach is novel in the context of septic shock, similar studies have shown promising results in other conditions related to CaSR expression.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients over the age of 18, * patients who have not participated in a study evaluating an investigational drug in the 30 days preceding the samples, * intensive care patients in a state of septic shock within the first 24 hours of the introduction of pressor amines, * French resident year-round, * lactate \> 2mmol/L, * patients with social security coverage. Exclusion Criteria: * Patients in hemorrhagic shock, * history of parathyroidectomy, patient with hypersecretion of PTHrp, * sarcoidosis, * genetic disturbance of CaSR including familial hypocalciuric hypercalcaemia, * current immunosuppressant treatment (anticalcineurin, mTOR inhibitor, methotrexate, high-dose corticosteroids excluding hydrocortisone and fludrocortisone), * chronic myelomonocytic leukemia, * patients with febrile neutropenia, * patients with acquired or constitutional immune system, * pregnant or breastfeeding patient, * patients under curators, guardianship or safeguard of justice.
Where it's running
-
CHRU Amiens
Amiens, France Recruiting
Study contacts
- Study coordinator: Quintana SOULIER
- Email: Soulier-Zaninka.Quintana@chu-amiens.fr
- Phone: 33+322057870
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adjunctive Fludrocortisone in Septic Shock on Hydrocortisone
In septic shock, this trial tests whether adding fludrocortisone (50 mcg or 100 mcg daily) to hydrocortisone improves survival and recovery compared with placebo.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
-
Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter
This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.
-
Personalized Fluid Resuscitation in the Emergency Department
This pilot test checks if a quick, non-invasive stroke-volume assessment can help ED doctors tailor IV fluids for septic patients with low blood pressure.
-
Discordance between capillary refill time and oxygen use in septic shock
This study tests whether some septic shock patients can have a normal capillary refill time but still lack tissue oxygen use, to see if that mismatch relates to 28-day survival.
-
Targeting upper-normal magnesium to see if norepinephrine needs drop in septic shock
This trial tests whether keeping magnesium levels at the upper end of normal can reduce the amount and duration of norepinephrine needed in adults with septic shock.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.